Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States [5]

Stroke

Volumn 37, Issue 4, 2006, Pages 943-944

  Scott, Phillip A ^a   Silbergleit, Robert ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN ISCHEMIA; COST CONTROL; DRUG UTILIZATION; ECONOMIC EVALUATION; HUMAN; LETTER; PRIORITY JOURNAL; REFERENCE VALUE; SENSITIVITY ANALYSIS; STROKE; CEREBROVASCULAR ACCIDENT; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; INTRAVENOUS DRUG ADMINISTRATION; NOTE; UNITED STATES;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INJECTIONS, INTRAVENOUS; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 33645823366     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000210181.05204.eb     Document Type: Letter

References (1)

1. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intraveneous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36:2500-2503.